Clinical Trials Browser

Phase 1 × OTHER × Rifaximin × Clear all

NCT03820817 2025-04-20

Rifaximin in Patients With Monoclonal Gammopathy

Phase 1 Active not recruiting

Waldenstrom Macroglobulinemia, Paraproteinemias

NCT00967096 2013-11-27

Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

Phase 1 Completed

Neoplasms